Le Lézard
Classified in: Health
Subject: SVY

South Korea Genetic Testing Market Outlook to 2024


NEW YORK, Nov. 20, 2017 /PRNewswire/ --  South Korea Genetic Testing Market Outlook to 2024

Summary

Read the full report: https://www.reportlinker.com/p03498805

GlobalData's new report, South Korea Genetic Testing Market Outlook to 2024, provides key market data on the South Korea Genetic Testing market. The report provides value, in millions of US dollars within market segments - Acquired Gene or Chromosome Alterations, Inborn Gene or Chromosome Alterations and Other Genetic Tests

The report also provides company shares and distribution shares data for each of these market segments, and global corporate-level profiles of the key market participants. Based on the availability of data for the particular market and country, information related to pipeline products, news and deals is available in the report.

Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis.

Scope
- Market size and company share data for Genetic Testing market segments - Acquired Gene or Chromosome Alterations, Inborn Gene or Chromosome Alterations and Other Genetic Tests
- Annualized market revenues (USD million) and volume (units) data for each of the market segments. Data is provided from 2010 to 2017 and forecast to 2024.
- 2017 company shares and distribution shares data for each of the market segments.
- Global corporate-level profiles of key companies operating within the South Korea Genetic Testing market.
- Key players covered include F. Hoffmann-La Roche Ltd, Abbott Laboratories and Luminex Corp.

Reasons to buy
- Develop business strategies by identifying the key market segments poised for strong growth in the future.
- Develop market-entry and market expansion strategies.
- Design competition strategies by identifying who-stands-where in the market.
- Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.
- What are the key distribution channels and what's the most preferred mode of product distribution - Identify, understand and capitalize.

Read the full report: https://www.reportlinker.com/p03498805

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

 

SOURCE Reportlinker


These press releases may also interest you

at 22:03
The report titled "Anti-Mullerian Hormone Test Market by Product (POC Testing, Self-check Kits), End-User (Commercial Labs, Research & development), Distribution, Use - Global Forecast 2024-2030" is now available on 360iResearch.com's offering,...

at 20:40
Rakovina Therapeutics Inc. a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for its fourth quarter and fiscal year ending December 31, 2023 and...

at 19:40
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the...

at 19:05
Appili Therapeutics Inc. (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced it has secured additional bridge financing in the amount of C$300,000...

at 19:00
David J. Dykeman, co-chair of the Life Sciences & Medical...

at 18:30
Aspire Health Alliance ("Aspire Health") is a company headquartered in Braintree, Massachusetts, that provides behavioral health services in the community.  Aspire Health experienced a data security incident that may have involved personal and...



News published on and distributed by: